Generic Name and Formulations:
Acamprosate calcium 333mg; e-c tabs.
Indications for CAMPRAL:
Maintenance of abstinence from alcohol in alcohol-dependent patients who are abstinent at treatment initiation, in conjunction with psychosocial support.
666mg 3 times daily. Renal impairment (CrCl 30–50mL/min): initially 333mg 3 times daily. Begin therapy during abstinence; continue during relapse.
Severe renal impairment (CrCl≤30mL/min). Sulfite allergy.
Moderate renal impairment (CrCl 31–50mL/min); reduce dose. Not a treatment for withdrawal symptoms. Monitor for suicidal ideation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
GI upset, myalgia/arthralgia, headache, rash, syncope, impotence, edema, palpitations; rare: kidney failure, suicidality.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Supported Employment vs Transitional Work in Veterans With PTSD
- Comparing Pharmacologic Treatments for Prevention of Rehospitalization in BP
- Preliminary Evidence Suggests Suicidal Thinking Is Self-Reinforcing
- Lower Fluoxetine Efficacy in Elderly Patients With Major Depressive Disorder
- Personal Health Information Found in Recycling